Impact of Early Natural Killer Cell Reconstitution on the Outcomes of T Cell-Replete Allogeneic Hematopoietic Stem Cell Transplantation
Ziwei Zhou,Xuan Liu,Xuejun Zhang,Shupeng Wen,Huan Hua,Zhenzhen Wang,Zheng Xu,Yu Lu,Fuxu Wang
DOI: https://doi.org/10.2147/jir.s416708
IF: 4.5
2023-07-20
Journal of Inflammation Research
Abstract:Ziwei Zhou, Xuan Liu, Xuejun Zhang, Shupeng Wen, Huan Hua, Zhenzhen Wang, Zheng Xu, Yu Lu, Fuxu Wang Department of Hematology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, Shijiazhuang, Hebei 050000, People's Republic of China Correspondence: Fuxu Wang, Department of Hematology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, No. 215 West Heping Road, Shijiazhuang, Hebei, 050000, People's Republic of China, Tel +86 13931100360, Fax +86 031166003936, Email Background: Early immune reconstitution is crucial to successful outcomes after allogeneic stem cell transplantation (allo-HSCT). However, in T cell-replete HSCT, the impact of natural killer (NK) cells on transplantation outcome and the factors influencing early NK cell reconstitution remain unclear. Methods: In this retrospective study, we analyzed 128 patients with hematological malignancies who received the first T cell-replete allo-HSCT between May 2019 and September 2021. After application of a conditioning regimen, prophylaxis for graft versus host disease (GVHD), and engraftment, the patients received prevention and treatment procedures for cytomegalovirus (CMV) reactivation. NK cells, T lymphocytes and B lymphocytes in peripheral blood were collected and analyzed at 30, 60, 90, 135 and 180 days after transplantation to observe immune cell reconstitution. Overall survival (OS), relapse-free survival (RFS), minimal residual disease (MRD), relapse, and non-relapse mortality (NRM) were evaluated. SPSS 25.0 and R version 4.2.1 were used for statistical analysis. Results: In patients with rapid NK recovery (NK cell count at 30 days post-HSCT [NK30] > 165/μL and 60 days post-HSCT [NK60] > 265/μL), we observed lower rates of NRM, CMV reactivation and acute GVHD (aGVHD). Multivariate analysis indicated that a lower NK30 (≤ 165/μL) was an independent factor associated with inferior OS and RFS. The NK30 and NK60 in patients with CMV reactivation and aGVHD after transplantation were significantly lower than those in patients without these complications. In addition, CD107a expression in NK cells was also significantly lower in patients who experienced aGVHD. Correlation analysis did not find an inhibitory effect of T-lymphocyte subset reconstitution on NK cells in the early stage after transplantation. Conclusion: Rapid NK cell reconstitution early after allo-HSCT had protective effects on NRM and survival. Promoting early NK cell reconstitution represents a new approach to improving the outcomes of allo-HSCT. Keywords: allogeneic hematopoietic stem cell transplantation, immune reconstitution, natural killer cells, T-cell replete, non-relapse mortality In recent years, allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been the only major method to cure hematological malignancies. However, disease relapse after HSCT, graft versus host disease (GVHD), infection and other transplant-related complications continue to drive high mortality rates among patients. Ex vivo T-cell depletion (TCD) of the graft uses either positive selection or negative depletion of graft cells before infusion to effectively reduce the incidence of GVHD after transplantation. In contrast, T cell-repleted grafts consisting of non-manipulated bone marrow or peripheral blood grafts require intense in vivo GVHD prophylaxis. 1,2 Rapid reconstitution of the immune system after transplantation can give full play to the graft versus leukemia (GVL) effect and reduce the incidence of related complications. Studies have demonstrated a low transplantation-related mortality (TRM) rate among patients with a high lymphocyte recovery rate. 3 Natural killer (NK) cells are the first lymphocyte subset to recover after allo-HSCT. They can exert cytotoxicity against residual leukemia cells and infected cells without antigen stimulation. 4,5 The killing activity of NK cells after HSCT depends mainly on the mismatch between killer cell immunoglobulin-like receptors (KIRs) on the surface of donor NK cells and the major histocompatibility complex (MHC) I class molecules in recipients. 6,7 NK cells have been shown to be the main effector cells that eliminate leukemia cells in T cell-depleted allo-HSCT. Stable implantation of NK cells after HSCT can improve the prognosis of patients, as shown by an early study of 54 patients with acute myeloid leukemia (AML) who received T cell-depleted allo-HSCT that revealed lower incidence rates of acute GVHD (aGVHD), relapse, and TRM among patients with rapid early NK cell recovery. 8 In recent years, additional research has shown that rapid reconstitution of NK cells in the early stage after T cell-depleted and HLA-mismatched HSCT can signific -Abstract Truncated-
immunology